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In 2017 over 550,000 estimated new cases of multi-drug/rifampicin resistant tuberculosis
(MDR/RR-TB) occurred, emphasizing a need for new treatment strategies. Linezolid
(LZD) is a potent antibiotic for drug-resistant Gram-positive infections and is an effective
treatment for TB. However, extended LZD use can lead to LZD-associated host toxicities,
most commonly bone marrow suppression. LZD toxicities may be mediated by IL-1,
an inflammatory pathway important for early immunity during M. tuberculosis infection.
However, IL-1 can contribute to pathology and disease severity late in TB progression.
Since IL-1 may contribute to LZD toxicity and does influence TB pathology, we targeted
this pathway with a potential host-directed therapy (HDT). We hypothesized LZD
efficacy could be enhanced by modulation of IL-1 pathway to reduce bone marrow
toxicity and TB associated-inflammation. We used two animal models of TB to test
our hypothesis, a TB-susceptible mouse model and clinically relevant cynomolgus
macaques. Antagonizing IL-1 in mice with established infection reduced lung neutrophil
numbers and partially restored the erythroid progenitor populations that are depleted
by LZD. In macaques, we found no conclusive evidence of bone marrow suppression
associated with LZD, indicating our treatment time may have been short enough to
avoid the toxicities observed in humans. Though treatment was only 4 weeks (the
FDA approved regimen at the time of study), we observed sterilization of the majority
of granulomas regardless of co-administration of the FDA-approved IL-1 receptor
antagonist (IL-1Rn), also known as Anakinra. However, total lung inflammation was
significantly reduced in macaques treated with IL-1Rn and LZD compared to LZD alone.
Importantly, IL-1Rn administration did not impair the host response against Mtb or LZD
efficacy in either animal model. Together, our data support that inhibition of IL-1 in
combination with LZD has potential to be an effective HDT for TB and the need for further
research in this area.
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INTRODUCTION
Tuberculosis (TB) remains the top cause of death by a single
infectious agent, with an estimated 10 million new cases of
active TB and 1.3 million deaths in 2017 alone (1). Antibiotic
treatment regimens are long and multi-drug resistant (MDR)
and extensive-drug resistant (XDR) Mycobacterium tuberculosis
(Mtb) strains have emerged, complicating treatment. Even those
patients that are cured of the infection can suffer permanent
deficits in lung function that result from inflammation and
fibrosis (2). Host-directed therapies (HDTs) have been proposed
as a potential option for improving therapy. Depending on
the strategy, HDTs can function to enhance antimicrobial
immune responses and shorten therapy, or inhibit pathological
inflammation (3). Since HDTs would be used as part of a multi-
drug regimen, targeting mechanisms that increase drug exposure
or decrease toxicity are also possible. While some HDT strategies
hold promise, very few have been rigorously tested in pre-clinical
models (4).
Interleukin-1 (IL-1) has been implicated in TB disease
severity and inflammation, making it a possible target of HDT.
This cytokine plays an important yet complicated role in TB
disease progression. The susceptibility of mice lacking critical
mediators of IL-1 signaling indicates that initial production of
IL-1 upon Mtb infection is essential for establishing protective
immune responses necessary for disease control (5–8). In
contrast, IL-1 production is regulated after the onset of adaptive
immunity, via multiple mechanisms including IFNγ production
(8), which acts via the induction of nitric oxide synthase 2
(NOS2)-dependent nitric oxide to inhibit IL-1β processing (9).
Persistent IL-1 signaling can contribute to the accumulation of
disease-promoting neutrophils in susceptible mice, and genetic
variants that result in higher IL-1β production are associated
with increased disease severity and neutrophil accumulation in
humans (9–11). Given that HDT is designed to be administered
to chronically infected patients during treatment when persistent
IL-1 production can play a pathological role, it could be beneficial
to block the inflammation and disease promoting activities of
this cytokine.
IL-1 may also play a role in the toxicity of linezolid (LZD),
an increasingly important antibiotic for the treatment of drug-
resistant TB, highlighted by its recent inclusion in a newly
approved therapy for MDR-TB (12). While LZD has shown
efficacy against XDR and MDR-TB, its wide-spread use has
been limited by severe host toxicities that occur after more
than 4 weeks of treatment (13, 14). Over the 6–20 month
treatment course necessary to treat resistant TB, both reversible
bone marrow suppression and irreversible neuropathies are
common clinical manifestations (15). LZD-associated toxicities
are generally attributed to the inhibition of mitochondrial
translation and LZD-mediated bone marrow suppression is
promoted by the subsequent mitochondrial damage. This
damage acts on the NOD-like receptor family, pyrin domain
containing 3 (NLRP3) protein that has been shown to be
necessary for LZD-mediated bone marrow suppression in mice
(16). NLRP3 forms an inflammasome complex containing
caspase-1, which cleaves a number of substrates resulting in cell
death and/or the release of active of IL-1β. While the importance
of NLRP3 in bone marrow suppression is clear, the relative roles
of inflammasome activation and IL-1 signaling remain uncertain.
Based on these studies, inhibiting the IL-1 pathway as a
potential HDT could serve two purposes: first, to alleviate LZD-
associated host toxicity and second, to reduce the pathology
associated with unchecked IL-1 signaling during TB disease.
Due to the pro-inflammatory nature of the IL-1 pathway,
strict regulatory mechanisms exist within the host to quell this
pathway. IL-1 receptor antagonist (IL-1Rn) is a protein produced
constitutively at low levels that can increase in response to a
variety of cytokine signals. IL-1Rn serves as a decoy ligand for the
IL-1receptor type 1 (IL-1R1), blocking signal transduction and
subduing activation of downstream pro-inflammatory pathways
(17). Anakinra is an FDA-approved recombinant IL-1Rn that
is used to treat rheumatoid arthritis and other inflammatory
disorders. As there are no FDA approved drugs to inhibit
inflammasome activation, inhibition of the IL-1 pathway with
biologics like Anakinra is currently the only feasible strategy to
modulate this pathway in humans (18).
We hypothesized that the combination of Anakinra (herein
referred to as IL-1Rn) with LZD for treatment of active TB disease
would reduce LZD-associated toxicities and host inflammation.
While there is little rationale to expect IL-1 blockade to
enhance bacterial clearance by the antibiotic, suppression of
both inflammation and LZD toxicity could provide a significant
benefit. To test this concept, we employed two established TB
animal models to assess differing aspects of host responses to
LZD and IL-1R1 blockade. We used multiple strains of mice to
model distinct disease states and dissect the relative importance
of the inflammasome and IL-1 signaling in evaluating HDT
efficacy. As a translational model, we used cynomolgus macaques
in combination with [18F] FDG PET CT serial imaging to
track TB disease progression, including inflammation, before
and during drug regimens (19). Cynomolgus macaques present
a similar spectrum of Mtb infection as humans with pathology,
granuloma structure and diversity, that recapitulates human TB
(20–22). Importantly, we designed our study in macaques to
reflect clinical standards, adhering to FDA guidelines for dosage
and time frame of LZD and IL-1Rn administration. Together,
our data indicate that IL-1 blockade alleviates LZD-mediated
bone marrow (BM) suppression in mice and may accelerate the
resolution of inflammation in both mice and macaques with TB.
MATERIALS AND METHODS
Ethics Statement
All experimental manipulations, protocols, and care of the
animals were approved by the University of Pittsburgh School
of Medicine Institutional Animal Care and Use Committee
(IACUC). The protocol assurance number for our IACUC is
A3187-01. Our specific protocol approval numbers for this
project are 15117082, 16017370, 18124275, 13011368, and
16027525. The IACUC adheres to national guidelines established
in the AnimalWelfare Act (7U.S.C. Sections 2131 - 2159) and the
Guide for the Care and Use of Laboratory Animals (8th Edition)
as mandated by the U.S. Public Health Service Policy.
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All macaques used in this study were housed at the
University of Pittsburgh in rooms with autonomously controlled
temperature, humidity, and lighting. Animals were singly housed
in caging at least 2 square meters that allowed visual and tactile
contact with neighboring conspecifics. The macaques were fed
twice daily with biscuits formulated for non-human primates,
supplemented at least 4 days/week with large pieces of fresh
fruits or vegetables. Animals had access to water ad libitum.
Because our macaques were singly housed due to the infectious
nature of these studies, an enhanced enrichment plan was
designed and overseen by our non-human primate enrichment
specialist. This plan has three components. First, species-specific
behaviors are encouraged. All animals have access to toys and
other manipulata, some of which will be filled with food treats
(e.g., frozen fruit, peanut butter, etc.). These are rotated on a
regular basis. Puzzle feeders foraging boards, and cardboard
tubes containing small food items also are placed in the cage to
stimulate foraging behaviors. Adjustable mirrors accessible to the
animals stimulate interaction between animals. Second, routine
interaction between humans and macaques are encouraged.
These interactions occur daily and consist mainly of small food
objects offered as enrichment and adhere to established safety
protocols. Animal caretakers are encouraged to interact with the
animals (by talking or with facial expressions) while performing
tasks in the housing area. Routine procedures (e.g., feeding, cage
cleaning, etc.) are done on a strict schedule to allow the animals
to acclimate to a routine daily schedule. Third, all macaques
are provided with a variety of visual and auditory stimulation.
Housing areas contain either radios or TV/video equipment that
play cartoons or other formats designed for children for at least
3 h each day. The videos and radios are rotated between animal
rooms so that the same enrichment is not played repetitively for
the same group of animals.
All animals are checked at least twice daily to assess
appetite, attitude, activity level, hydration status, etc. Following
M. tuberculosis infection, the animals are monitored closely
for evidence of disease (e.g., anorexia, weight loss, tachypnea,
dyspnea, coughing). Physical exams, including weights, are
performed on a regular basis. Animals are sedated prior to all
veterinary procedures (e.g., blood draws, etc.) using ketamine
or other approved drugs. Regular PET/CT imaging is conducted
on most of our macaques following infection and has proved
very useful for monitoring disease progression. Our veterinary
technicians monitor animals especially closely for any signs
of pain or distress. If any are noted, appropriate supportive
care (e.g., dietary supplementation, rehydration) and clinical
treatments (analgesics) are given. Any animal considered to have
advanced disease or intractable pain or distress from any cause
is sedated with ketamine and then humanely euthanatized using
sodium pentobarbital.
Mice, Infection and Treatment
C57BL/6 (stock no. 000664), Nos2−/− (B6.129P2-Nos2tm1Lau/J,
stock no. 002609), C3HeB/FeJ (stock no. 00658), and Nlrp3−/−
(B6.129S6-Nlrp3tm1Bhk/J, stock no. 021302) were purchased
from the Jackson Laboratory. Breeding pairs of Caspase-
1/11 double knock-out mice were kindly provided by Prof.
Katherine Fitzgerald of the Department of Infectious Diseases
at University of Massachusetts (UMASS) Medical School and
bred in house. Mice were housed under specific pathogen-free
conditions, and in accordance with the UMASS Medical School,
IACUC guidelines.
Unless otherwise indicated, all mice used in this study were of
C57BL/6 background, male, and 8–12 weeks of age at the time
of infection.
The wild type strain of M. tuberculosis (Mtb) Erdman was
used in these studies. Bacteria were cultured in 7H9 medium
containing 0.05% Tween 80 and OADC enrichment (Becton
Dickinson). For infections, mycobacteria were suspended in
phosphate-buffered saline (PBS)-Tween 80 (0.05%); clumps were
dissociated by sonication, and ∼100 CFU were delivered via the
respiratory route using an aerosol generation device (Glas-Col,
Terre Haute, IN). At indicated time points mice were treated
with 200 mg/kg of Linezolid (LZD). These drugs were prepared
in 0.5% carboxymethyl cellulose (CMC) and Polyethylene glycol
300 solution as the vehicle. Cohorts of mice were treated with
anti-IL-1R1 antibody (InVivoMab, anti-mouse IL-1R, Clone
JAMA147, BioXcell), either alone or in combination with LZD.
0.5% CMC and Polyethylene glycol was used as vehicle control.
All antibiotic treatment was done by daily oral gavage. Anti-IL-
1R1 (100 µg/mouse/0.2mL) was administered every alternate
day by subcutaneous and intraperitoneal route. All data from
these studies are available in the Supplementary Data Sheet.
Macaque Pharmacokinetic Study and
Analytical Method
Uninfected macaques designated for other studies (n = 3)
were given 20 mg/kg or 40 mg/kg of LZD by oral gavage and
plasma acquired at 0, 5, 19, 15, 20, 25, and 30 h post LZD
administration. High pressure liquid chromatography coupled to
tandem mass spectrometry (LC/MS-MS) analysis was performed
on a Sciex Applied Biosystems Qtrap 4000 triple-quadrupole
mass spectrometer coupled to an Agilent 1260 HPLC system
to quantify LZD in macaque plasma. LZD chromatography was
performed on an Agilent Zorbax SB-C8 column (2.1 × 30mm;
particle size, 3.5µm) using a reverse phase gradient elution.
Milli-Q deionized water with 0.1% formic acid was used for the
aqueous mobile phase and 0.1% formic acid in acetonitrile for
the organic mobile phase. Multiple-reaction monitoring (MRM)
of parent/daughter transitions in electrospray positive-ionization
mode was used to quantify the analytes. Sample analysis was
accepted if the concentrations of the quality control samples
were within 20% of the nominal concentration. Data processing
was performed using Analyst software (version 1.6.2; Applied
Biosystems Sciex).
Neat 1 mg/mL DMSO stocks for all compounds were serial
diluted in 50/50 Acetonitrile water to create standard curves
and quality control spiking solutions. Twenty microliter of neat
spiking solutions were added to 20 µL of drug free plasma
or control tissue homogenate, and extraction was performed
by adding 180 µL of Acetonitrile/Methanol 50/50 protein
precipitation solvent containing the internal standard (10 ng/mL
verapamil and deuterated LZD-d3). Extracts were vortexed
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for 5min and centrifuged at 4,000 RPM for 5min. Hundred
microliter of supernatant was transferred for LC-MS/MS analysis
and diluted with 100 µL of Milli-Q deionized water.
Rhesus macaque plasma (Lithium Heparin, Bioreclamation
IVT, NY) was used as a surrogate to cynomolgus macaque
plasma to build standard curves. LZD-d3 internal standard and
verapamil were purchased fromToronto Research Chemical. The
lower and upper limits of quantitation (LLOQ andULOQ)were 1
and 50,000 ng/mL, respectively. The following MRM transitions
were used for LZD (338.00/235.00), LZD-d3(341.20/297.20), and
verapamil (455.40/165.20).
Macaques, Infection and Treatment
All housing, care, and experimental procedures were approved
by the University of Pittsburgh School of Medicine Institutional
Animal Care and Use Committee (IACUC). Examination of
animals was performed in quarantine to assess physical health
and confirmation of no previous M. tuberculosis infections
as previously described (23). Cynomolgus macaques (Macaca
fascicularis) (N = 10) were purchased for this study from
(Valley Biosystems). Bone marrow control (non-drug treated)
samples were taken from Mtb-infected cynomolgus macaques
in unrelated ongoing studies (N = 5). For the current study,
all 10 animals were infected bronchoscopically with 12 CFU
of Mtb strain Erdman. After active disease developed (3–5
months), NHPs were randomized to LZD only (N = 5) or
LZD+IL-1Rn (N = 5) treatment groups. For randomization,
macaques were paired based on total FDG activity in lungs
(a surrogate for total thoracic CFU), and then assigned to
treatment by coin flip (20). LZD was administered twice a
day orally with food (30 mg/kg), while IL1-Rn was given at 2
mg/kg once each day by subcutaneous injection. All animal data
are provided in Supplementary Table 1. Medication compliancy
was monitored at every administration and pharmacokinetic
analysis performed at select times. Drug treatments were
administered for 4 weeks prior to necropsy. Bronchoalveolar
lavages (BAL) were performed prior to drug-treatment and 3
weeks-post start of treatment for CFU, flow cytometry and
multiplex assays.
Macaque PET/CT Imaging
Positron emission tomography (PET) with computed
tomography (CT) imaging was performed with 2-deoxy-2-
[18F]-D-deoxyglucose (FDG) throughout the study as previously
described (19). Serial scans were performed throughout the study
to track disease progression and changes during drug treatment.
Total FDG activity of the lungs was measured over the course
of infection and drug treatment as previously described (19).
Granulomas identified on scans were denoted, measured (mm)
and standard uptake values (SUVR) were determined to assess
metabolic activity, a readout for inflammation. SUVR values
were normalized to muscle and SUVR and size measurements
were determined at each scan over time to compare pre-and
post-drug treatment. Each animal was scanned prior to necropsy
to identify granulomas for matching at necropsy; granulomas
≥1mm are distinguishable by PET/CT.
Macaque Necropsy
Necropsies were performed as previously described. In short,
multiple tissues (granulomas, lung lobes, thoracic lymph nodes,
peripheral lymph nodes, liver, spleen, bone marrow) were excised
and homogenized into single-cell suspensions for assessment
of bacterial burden and immunological assays. Granulomas
were individually excised (PET/CT identified and others not
identified on scans) and split (size permitting) with one-half for
homogenization and single cell suspension and the other half
processed for histological analysis. Bone marrow samples were
obtained from the sternum, with a portion sent for histological
analysis while single cell suspensions were acquired as previously
described (24). Bacterial burden was assessed from each tissue by
plating serial dilutions on 7H11 agar plates and incubated at 37◦C
in 5% CO2 for 21 days before enumeration of Mtb CFU.
Flow Cytometry and Immunoassays
Mice
Single cell suspensions were prepared from the infected mouse
organs. Briefly, lung tissue was digested with Collagenase type
IV/DNaseI and passed through 40µm cell strainers to obtain
single cell suspension. Red blood cells were lysed using Tris-
buffered Ammonium Chloride (ACT) Non-specific antibody
binding sites were blocked by Fc-Block CD16/32 (Clone 93,
cat. no. 101319) and the cells were stained with anti-CD3-
PE (Clone 17A2, cat. no. 100205), anti-CD11b-PerCP Cy5.5
(Clone M1/70, cat. no.101227), anti-Ly-6G-FITC (Clone 1A8,
cat. no.127605), anti-Ly-6C-PE (Clone HK1.4, cat. no.128007),
anti-Gr1-APC (Clone RB6-8C5, cat. no.108411), anti-Ter119-PE
(Clone TER119, cat. no.116208), anti-CD71-FITC (clone RI7217,
cat. no. 113806). Antibodies were purchased from BioLegend. All
analyses were performed on live cells only after staining them
with fixable live dead stain conjugated with eFlour780, purchased
from eBiosciences. All the staining was done according to the
manufacturer’s instructions. Lung, spleen and bone marrow cells
were surface stained for 30min at room temperature, fixed for
20min at 4◦C using the Cytofix buffer (BD-Biosciences, cat. no.
554655). Data were acquired in a BD LSRII flow cytometer in
the flow cytometry core facility at UMASS medical school and
analyzed with FlowJo Software (Treestar, Inc.). Gating strategies
are provided in applicable figures.
Macaques
Single cell suspensions acquired from homogenization of
granulomas, lung lobes, and lymph nodes were subjected to
intracellular cytokine staining (ICS). Prior to staining, cells
were incubated in RPMI 1640 containing 1% HEPES, 1%
L-glutamine, 10% human AB serum, and 0.1% brefeldin A
(Golgiplug; BD Biosciences) for 3 h at 37◦C in 5% CO2.
After viability staining (Invitrogen), surface antigens and
intracellular cytokines were assessed using standard protocols.
Surface markers include CD3 (SP34-2; BD Pharmingen), CD4
(L200; BD Horizon), CD8 (RPA-T8; BD Horizon) for T
cells and CD11b (ICRF44; BD Pharmingen), CD206 (19.2;
BE Pharmingen) for macrophages/neutrophils. Calprotectin
(27E10; ThermoFisher) was stained intracellularly to identify
neutrophils. For bone marrow, single cell suspensions underwent
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red blood cell lysis (BD Pharm Lyse) before incubation in
alpha-MEM + 10% StasisTM FBS (Gemini Bio-Products) +
MitoTrackerTM Red CMXRos (Invitrogen) for 30min to stain for
membrane potential of mitochondria. Cells were then stained for
viability (Invitrogen) and surface stained to distinguish erythroid
progenitor populations by CD34 (581; Biolegend), CD235a
(HIR2; BD Pharmingen), CD71 (L01.1; BD Pharmingen), and
CD45 (D058-1283; BD Pharmingen). All samples were acquired
on an LSR II (BD) and analyzed with FlowJo Software (Treestar,
Inc.). Gating strategies are provided in applicable figures.
For the multiplex assays, all samples and supernatants
were stored at −80◦C from time of necropsy until time
of assay. Five representative granuloma supernatants were
randomly selected from each animal using JMP Pro v12 (SAS
Institute Inc.). Supernatants were thawed and filtered with a
0.22µM syringe filter to remove infectious bacteria and debris,
then kept on ice throughout the assay. For BAL samples,
supernatants were concentrated using regenerated cellulose
centrifugal filter tubes (3,000 NMWL, Millipore Sigma) to a
final 10X concentration (5 to 0.5mL). Both granuloma and
BAL supernatants were evaluated with a ProcartaPlex multiplex
immunoassay (Invitrogen) that assesses thirty cytokines and
chemokines specific for NHPs. We followed the manufacturer’s
protocol with one modification in which we diluted the standard
out an extra dilution to increase the range of detection. Results
were analyzed by a BioPlex reader (BioRad).
Histopathology and Immunofluorescence
Mice
Lung tissues were fixed in 10% buffered formalin and embedded
in paraffin. Five micrometer-thick sections were stained with
hematoxylin and eosin (H&E). Tissue staining was done by
the Diabetes and Endocrinology Research Center histopathology
core facility at the University of Massachusetts Medical School
or immunology core facility of Albany medical college, NY.
Brightfield images were acquired in Abaxis VETSCAN HD
microscope. Lesion size in the histopathological sections were
measured using the Image J image analysis software, and
percentage of lesion area was calculated relative to the total
lung area.
Paraffin embedded lung tissue sections were cut at 5µm
thickness, mounted on ultraclean glass slides covered in silane,
deparaffinized, then dehydrated and rehydrated using the
following steps: Ethanol solutions (30, 50, 70, 90, 95, and 100 %
for 3min each), xylenes (2 different solutions for 10min each)
and ethanol solutions (100, 95, 90, 70, 50, and 30 for 3min
each). The slides were washed once in Tris buffer saline (TBS)
for 5min. Slices were subjected to antigen retrieval by boiling in
sodium citrate buffer at pH = 6.0 for 20min and incubated in
0.1% Triton-X 100 for 5min. Slices were removed and allowed to
equilibrate to room temperature for at least 20min and rinsed
with distilled water. Tissue sections were blocked (blocking
solution; 0.5M EDTA, 1% BSA, in PBS) and incubated overnight
in primary antibodies against the proteins related to our studies.
Sections were stained for nuclei (DAPI, blue staining), anti-
mouse CD3e (cat.no. ab16669, green staining), anti-mouse Ly-6G
(clone 1A8, cat. no. 127602) to identify neutrophil granulocytes
(Cy3, red staining). As controls, pre-immune serum and isotype
matched controls were used. After incubation, the tissues were
washed several times with sterile TBS at room temperature and
incubated in the respective secondary antibodies (anti-rabbit
conjugated to Alexa-488, anti-rat conjugated to Cy3) for at least
2 h at room temperature. Tissue sections were mounted using
Prolong Gold Antifade reagent (Invitrogen, grand Island, NY)
with DAPI, and the tissue sections were examined in ECHO
Revolve 4 microscope. Isotype matched control antibodies were
used for checking antibody specificity.
Macaques
As previously described, samples acquired at necropsy were
formalin fixed, paraffin embedded, cut into ∼5µm serial
sections and stained with H&E (23). A study-blinded veterinary
pathologist assessed and characterized each granuloma,
indicating size, type, distribution and cellular composition.
Sterna for bone marrow analysis were excised and formalin fixed
then transected longitudinally into 1 to 2 sternebral unites and
placed in Cal-Ex Hydrochloric acid decalcification solution for
2–4 h. Upon removal, specimens were washed and trimmed to
test for adequate mineral removal, then submitted for routine
tissue processing with other tissue specimens as described above.
Statistical Analysis
Mouse Studies
Equal variance between samples was assessed by Brown-Forsythe
test. Experiments in which variances were equivalent were
analyzed by one-way ANOVA with Sidak’s multiple comparisons
test. Those with unequal variances were analyzed by Welch
ANOVA and Dunnett’s multiple comparisons test. P < 0.05 was
considered significant.
Macaque Studies
Nonparametric U-tests (Mann-Whitney) were performed
for two-group comparisons and Kruskal-Wallis tests were
performed for three-group comparisons as indicated on data
sets with non-normal distributions. Wilcoxon signed rank tests
were performed for matched pairs. Fisher’s exact test was run
on any categorical data. P < 0.05 were considered significant.
Total lung FDG activity was log10-transformed. Note that for any
log-transformed data, a log10(x+ 1) transform was implemented
so that zeroes were not excluded from the graphs or analyses.
A two-way ANOVA was utilized to test whether treatment or
time (or an interaction between these factors) had an effect on
total lung inflammation. Time was found to be a statistically
significant effect (p = 0.0046); therefore, Dunnett’s multiple
comparison tests were then used to compare each time point to
pre-drug treatment within each treatment group. For bivariate
data, a linear regression was used to test the linear relationship
between the variables and the R2 and p-value for the F-test are
reported in the accompanying figure legend. Statistical analyses
were performed in GraphPad Prism 8 (GraphPad Software, San
Diego, CA). A regression equation created from control animals
from previous studies was used to create a 95% prediction
interval for total thoracic bacterial burden using total lung FDG
activity on the scan just before drug treatment (20). The lower
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and upper bounds and the mean of this prediction interval were
subtracted from each animal’s total CFU to estimate change in
CFU over the course drug treatment. All statistical analyses are
referenced in the corresponding figure legends.
RESULTS
IL-1 Receptor Blockade Reduces
Inflammation in Mouse Models of TB
Disease
Given the complex role played by IL-1 during TB, we initially
sought to determine the effect of inhibiting this cytokine
during TB disease in mice. We used a blocking antibody to
the murine IL-1 receptor type 1 (αIL-1R1) since this reagent
has been shown to alter TB disease in mice (25), and we
previously found that recombinant human IL-1Rn (Anakinra)
has little effect in this mouse model. Two mouse strains were
employed to assess the effects of these treatments in animals
with different amounts of IL-1 activity. In relatively resistant
C57BL/6 animals, mature IL-1 production is controlled by IFNγ-
dependent nitric oxide production, whereas unregulated IL-1
drives inflammatory disease characterized by increased number
of neutrophils (PMNs), bacterial burden (CFU) in the lungs and
significant weight loss observed in Mtb-infected Nos2−/− mice
that lack this regulatory pathway (9, 10).
αIL-1R1 was administered to the animals between days 14
and 28 post infection after the onset of adaptive immunity. In
both resistant (C57BL/6) and susceptible (Nos2−/−) mice, αIL-
1R1 treatment significantly reduced PMN numbers in the lungs.
In addition, this treatment reversed the weight loss observed
in Nos2−/− animals (Figures 1A,B). Somewhat surprisingly,
this regimen also modestly reduced the mean bacterial burden
in lungs and spleens, with this reduction meeting statistical
significance in the spleens of Nos2−/− mice (Figures 1C,D).
This generally beneficial effect of αIL-1R1 treatment was
consistent with qualitatively improved histopathological disease
(Figures 1E,F). By no metric did this αIL-1R1 treatment
exacerbate disease in either mouse strain.
IL-1 Blockade Alleviates Lung
Inflammation and Hematopoietic
Suppression During LZD Treatment in Mice
The IL-1R1 blocking antibody was next tested in combination
with LZD to determine whether the efficacy or toxicity of the
antibiotic was altered. C3HeB/FeJ mice, which are relatively
susceptible to Mtb and develop histopathological lesions that
more closely resemble human disease, were used for these
studies. To model established disease, mice were treated between
days 28 and 46 post-infection with vehicle alone, LZD, αIL-
1R1 or a combination of the two. As previously reported,
LZD was effective in this model, reducing lung neutrophil
numbers, bacterial burden and weight loss (Figures 2A–D)
(26). The addition of αIL-1R1 to this regimen further reduced
lung neutrophil numbers. IL-1 blockade had very little effect
on bacterial burdens in lung or spleen, whether given alone
or in conjunction with LZD. The mean CFU burden in
αIL-1R1-treated animals was within 2.3-fold of the untreated
groups, and only the αIL-1R1-associated decrease in the spleens
of LZD treated animals approached significance. As IL-1β
production in response to both Mtb infection (9) and LZD
treatment (16) depends largely on the NLRP3 inflammasome,
we also investigated a regimen in which LZD and a small
molecule NLRP3 inhibitor (MCC950) was administered between
days 56 and 77 post-infection. As observed with αIL-1R1,
the addition of MCC950 reduced PMN numbers in the
lung, relative to LZD alone, and did not significantly alter
bacterial killing (Figures 2E–G). Using a more rapid treatment
protocol and C57BL/6 mice with genetic deficiencies in
Caspase 1 or NLRP3, we confirmed that the antimicrobial
activity of LZD was unaffected by inflammasome activation
(Supplementary Figures 1A–D). Mice were treated between
days 14 and 28 post-infection and the effect of LZD on bacterial
burden and lung neutrophil number was at least as large in the
knockout animals as the wild type controls.
Next, we evaluated the hematopoietic suppression caused
due to LZD treatment in the bone marrow and spleens of
C3HeB/FeJ mice. In small animals, bone marrow serves as the
primary site of hematopoiesis, but during infection or stress,
the spleen functions as an extramedullary hematopoietic organ
to compensate for the increasing demand of blood cells in the
periphery (27). As LZD did not alter the myeloid cells in the bone
marrow (data not shown), and previous reports have shown its
effects on erythropoiesis (16), we investigated the effect of this
oxazolidinone on erythroid lineage cells in both these organs.
Using flow cytometry, erythroid progenitors can be divided into
a progression of precursors: pro-erythrocyte (ProE), EryA, EryB,
and EryC (Figure 3A). These populations were quantified in each
tissue of Mtb-infected animals treated with LZD and/or αIL-
1R1. In both bone marrow and spleen, LZD had a profound
effect, nearly eliminating early erythroid progenitors of the ProE,
EryA, and EryB classes (Figures 3B–G). Simultaneous treatment
with αIL-1R1 largely reversed the effect of LZD in the spleen,
restoring these immature precursors to approximately half of
their untreated levels. While αIL-1R1 also significantly increased
the number of erythroid precursors in the BM, the suppression of
LZD toxicity was less pronounced at this site.
In sum, studies in the mouse model indicated that the
addition of αIL-1R1 to an LZD regimen could reduce the number
of lungs PMN and ameliorate hematopoietic toxicity, while
not compromising antimicrobial activity. These observations
justified further studies in a non-human primate model.
Changes in TB Disease in Macaques
Treated With LZD and HDT by PET/CT
Previously we published the efficacy and pharmacokinetics of
LZD in cynomolgus macaques treated for 8 weeks with a single
daily dose of 30mg/kg (14). To adhere to FDA guidelines for LZD
administration at the time we initiated this study and reproduce
clinical exposure at 600mg twice daily (b.i.d.), we shortened
treatment duration to 4 weeks and increased the dosing
frequency to 30mg/kg b.i.d. Dose finding studies were carried out
in uninfected cynomolgusmacaques to ensure that adequate drug
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FIGURE 1 | IL-1 inhibition in susceptible mice reduces inflammation with no effect on lung bacterial burden. Wild type C57BL/6 and Nos2−/− mice were infected with
Mtb Erdman for 2 weeks and treated with anti-IL-1R1 (αIL-1R1) for the subsequent 2 weeks. (A) Lung neutrophil/PMN (CD45+ CD11b+ Ly-6C− CD3e−Ly-6G+),
T-cell (CD45+ Ly6C−LyG−CD3e+), and Monocyte/macrophage (CD45+ CD11b+ Ly-6G− CD3e− Ly6C+) recruitment to the lung among different treatment groups
were quantified by flow cytometry. (B) Weight loss and (C) CFU in lung and (D) spleen are shown. Data shown (mean ± SD) are representative of two independent
experiments. One-way ANOVA with Sidak’s multiple comparisons-test was used. N = 4 mice per treatment cohorts. (E) Histopathology analysis of a single lung lobe
from WT or Nos2−/− mice was performed by Hematoxylin-eosin (H&E) staining and (F) Lesion size was quantified by analyzing the histopathological images from
each mouse lung among treatment groups (n = 4). Data shown are expressed as Mean ± SD. One-way ANOVA with Tukey’s multiple comparison test was applied to
calculate the p-value.
concentrations similar to those achieved in patients at 600mg
b.i.d. were reached in the blood (Supplementary Figure 2).
To assess this LZD regimen and HDT with IL-1Rn,
we infected 10 cynomolgus macaques with Mtb strain
Erdman and monitored development of active TB disease
(Supplementary Table 1 and Supplementary Figure 2). Infected
macaques were then randomized to a 4 week drug regimen of
LZD (n= 5) or LZD+IL-1Rn (n= 5) (Supplementary Figure 2).
Our model has the advantage of tracking disease progression
throughout infection and treatment using serial 18F-FDG PET
CT scans (14, 28). Lung inflammation quantified by total FDG
activity in the lungs is correlated with total thoracic bacterial
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FIGURE 2 | IL-1R1 blockade combined with Linezolid ameliorates TB disease. (A–D) C3HeB/FeJ mice were infected with Mtb Erdman for 4 weeks and treated with
linezolid (LZD) and/or anti-IL-1R1 (αIL-1R1) for the following 18 days. (A) Lung neutrophils were quantified by flow cytometry; (B) Percent change in body weight is
shown and (C) Bacterial burden in the lung and (D) spleen were quantified as CFU. Data shown (Mean ± SD) are representative of two independent experiments.
Welch ANOVA with Dunnett’s post-test was used to calculate statistical significance where each treatment group was compared to the vehicle as control group.
N = 3–5 mice per treatment group. (E–G) C3HeB/FeJ mice were infected with M. tb Erdman for 8 weeks and treated with linezolid (LZD) and/or an inhibitor of the
NLRP3 inflammasome (MCC950) for the following 21 days. (E) Lung neutrophils were quantified by flow cytometry. (F) Bacterial burden in the lung was quantified by
CFU. Data shown (Mean ± SD) are from one experiment. One-way ANOVA with Tukey’s multiple comparison test was used to calculate the p-value. N = 4–5
mice/group. (G) Representative immunofluorescence images of the lungs from different treatment groups. Cell nuclei stained with DAPI (blue), T-cells stained with
anti-mouse CD3ε (green) and neutrophils stained with anti-mouse Ly-6G (red).
burden as previously described (19). Here we quantified total
lung FDG activity before and during treatment. 3D rendered
images provide a visual for changes in overall lung inflammation
in the “best” and “worst” animals for both treatment groups
(Figure 4A). Quantification of total lung FDG showed no
significant difference in inflammation at time of necropsy
between LZD and LZD+IL-1Rn treatment groups (Figure 4B),
however a slight change in slope with IL-1Rn treatment was
observed. To expand on this finding and test if LZD+IL-1Rn
reduced total lung FDG activity more effectively than LZD alone
over time, we compared the change in FDG activity between 0,
2, and 4 weeks post treatment. In LZD only treated macaques,
there was no significant decrease in total lung FDG activity
after 2 (p = 0.0857) and 4 weeks of treatment (p = 0.2876)
(Figure 4B). In contrast, LZD+IL-1Rn treatment resulted
in a significant reduction in total lung FDG activity after 2
and 4 weeks (p = 0.0242, p = 0.0237, respectively). To assess
whether these changes in lung inflammation were reflected
in individual granulomas, we used PET CT scans acquired
pre-treatment and at 4 weeks post-treatment to determine
changes in granuloma physical size (mm) and metabolic activity
as Standard Uptake Value (SUVR) of FDG per granuloma
(Figures 4C,D) (19). Differences in size and SUVR as presented
as the fold change from pre-treatment to necropsy. SUVR
indicates the inflammatory state of each individual granuloma,
allowing us to track specific lesions throughout treatment
for changes in activity. After treatment, while the majority of
granulomas decreased in size and SUVR, there was variability
within an animal and between animals resulting in no significant
differences between LZD and LZD+IL1-Rn treated animals.
These data indicate that blocking of IL-1R in combination with
LZD reduces total lung inflammation more efficiently than
LZD alone.
Addition of IL-1Rn Does Not Alter LZD
Bacterial Clearance
IL-1Rn does not have direct bactericidal activity, therefore
addition of IL-1Rn to LZD treatment should not directly
influence bacterial killing and burden. However, to ensure
immunomodulation with IL-1Rn did not have detrimental
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FIGURE 3 | Erythropoiesis associated with LZD treatment was partially relieved after IL-1R1 blockade. C3HeB/FeJ mice were infected with Mtb Erdman for 4 weeks,
and treated with LZD either alone or in combination with anti-IL-1R1 antibody for the subsequent 18 days. (A) Gating strategy for detecting erythroid progenitors is
shown. Erythroid progenitors in the spleen (B–D) and bone marrow (E–G) were quantified by flow cytometry as described in Materials and Methods. Representative
flow cytometry plots, percent, and total numbers of the early erythroid progenitors (sum of Pro-Ery, EryA, EryB) among different treatment groups are shown (C,F). Cell
numbers in each subset are also shown (D,G). Data shown (Mean ± SD) are from two independent experiments. One-way ANOVA with Dunnett’s post-test was
applied to calculate the p-value by comparing the mean of each group with that of LZD treated group. N = 3–5 mice per group.
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FIGURE 4 | HDT reduces granuloma inflammation by PET/CT in macaques. Cynomolgus macaques were infected with Mtb Erdman for approximately 4 months (see
Supplementary Table 1) and randomized to treatment with LZD or LZD+IL-1Rn for an additional 4 weeks. PET CT scans were performed pre-treatment 0, 2, and 4
weeks post-treatment with 4 week scans as the last prior to necropsy. (A) 3-D renderings of PET/CT scans from pre-treatment and 4 weeks post-treatment are
depicted, with “best” and “worst” of each group referring to TB disease prior to drug administration. (B) Total lung FDG activity of each macaque throughout treatment
with LZD (left) or LZD+IL-1Rn (right). Two-way ANOVA with Dunnett’s adjusted p-values are reported. (C) Individual granulomas were identified pre-treatment and
tracked post-treatment by PET/CT. Change in size (by CT) was determined for granulomas from each animal; the median (left) change in granuloma size from each
animal and individual granulomas per animal (right). (D) Standard uptake value (SUVR) of 18F-FDG was calculated for each granuloma, representing inflammation. The
median fold change in SUVR of all granulomas (left) and change in SUVR of individual granulomas from each animal (right) are shown. Mann-Whitney tests determined
p-values for (C,D), with p < 0.05 considered significant.
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effects on host antibacterial immune responses, we performed
comprehensive bacterial burden analysis at necropsy as
previously described (20). In short, we acquired individual
granulomas identified by PET CT as well as other TB
pathologies, thoracic lymph nodes, uninvolved lung tissue
and extrapulmonary lesions for bacterial plating and CFU
determination. Total thoracic CFU (lung + lymph nodes) was
not significantly different between LZD and LZD + IL-1Rn
in macaques (p = 0.1508). Similarly, separate analysis of lung
CFU excluding thoracic lymph nodes did not demonstrate
significant differences between groups (p = 0.5476) (Figure 5A).
We did not have untreated control macaques available in this
study, therefore we provide total thoracic CFU for 3 historical
control animals that were similarly infected and necropsied at
a similar time point; these data serve as reference for expected
CFU at this time point and were not included in statistical
analyses. While the treatment groups had similar frequencies of
sterilized granulomas (LZD= 68.42%, LZD+IL-1Rn= 72.22%),
it is important to note that the majority of granulomas were
sterilized during the short 4 week course of LZD or LZD+IL-1Rn
treatment. We previously reported that a 2-month lower dose
regimen of LZD could reduce bacterial burden compared to
untreated controls, with ∼80% sterilized granulomas in treated
animals and ∼20% sterilized in untreated (14). This supports
that high dose LZD as a single drug is effective at killing bacteria
even in a short (4 week) regimen. The lymph nodes are a
recently identified reservoir for Mtb and a hub for immune cell
interactions (29), therefore we assessed HDT effects on bacterial
burden in thoracic lymph nodes after treatment. We saw no
significant difference in overall lymph node CFU nor CFU per
lymph node (Figure 5B), indicating addition of IL-1Rn did
not measurably alter LZD efficacy or antibacterial immunity in
lymph nodes. To better understand the efficacy of high dose
LZD for 4 weeks, we estimated the pre-treatment total thoracic
CFU for each macaque using the total lung FDG by PET CT
as previously described (20), and compared the true bacterial
burden post-treatment against the estimated pre-treatment
value (Figure 5C). This analysis allows us to estimate the
magnitude of LZD bacterial killing during LZD and LZD+IL-
1Rn treatment. All macaques had lower total thoracic CFU at
necropsy compared to the estimated total thoracic CFU prior
to treatment start and on average the total CFU was ∼100-fold
lower than estimated CFU prior to treatment (Figure 5C). Our
data indicate that while IL-1Rn did not significantly enhance
bacterial killing, it did not impair LZD-mediated bacterial
clearance, an important observation for HDT development.
Lack of LZD-induced Bone Marrow
Suppression in Macaques
In humans, LZD is associated with host toxicities during
extended treatment periods of >4 weeks (30) resulting in the
FDA limitation of LZD to <4 weeks for most indications. We
designed our study in macaques to follow FDA-guidelines for
transition to possible human trials, therefore the potential for
bonemarrow toxicity to occur within this timeframe inmacaques
was unknown. To determine whether bone marrow suppression
occurred during the 4 week high dose LZD therapy and
whether IL-1Rn could modulate any observable host toxicities,
we isolated bone marrow at necropsy from the sternum of each
macaque and assessed erythropoietic progenitor populations and
mitochondrial function by flow cytometry (Figure 6A). During
homeostatic erythropoiesis, a 1:8 ratio is maintained between
ProE and EryC progenitor populations. Changes in this ratio can
be used to indicate disruption of erythropoiesis. In macaques,
there was no significant difference in ProE:EryC ratios between
the treatment groups (Figure 6B). We also analyzed control
bone marrow from untreated Mtb-infected macaques involved
in other on-going studies (TB only), which showed no significant
difference between ProE:EryC ratios compared to treatment
groups. To determine whether LZD was affecting mitochondrial
function, we stained bone marrow cells with MitoTrackerTM
Red CMXRos which only stains mitochondria with active
membrane potential, indicating function of those organelles
(Figure 6B). Regardless of treatment, the MitoTracker MFI
remained similar, indicating that mitochondrial function is the
same among groups. To confirm our observations, a pathologist
evaluated bone marrow tissue sections and found no observable
differences between TB only, LZD and LZD+IL-1Rn groups in
terms of cellularity (myeloid:erythroid ratios) or abnormalities
(Figure 6C). We could not consistently identify progenitor
populations in blood or spleen, therefore we performed complete
blood counts (CBCs) during treatment to identify signs of bone
marrow suppression (i.e., anemia, thrombocytopenia). There
were no observable differences between LZD and LZD+IL-1Rn
treatments (Supplementary Figure 3). In conclusion, 4 weeks
of LZD was not sufficient to induce observable bone marrow
suppression in cynomolgus macaques and blocking of IL-1R did
not alter bone marrow status during LZD treatment of TB.
Reduction in Neutrophil Signatures in the
Lung During LZD and LZD_IL-1Rn
Treatment
To determine whether addition of IL-1Rn to LZD treatment
modulated immune populations similar to observations in the
mouse model, bronchoalveolar lavages (BAL) were acquired
prior to the start of treatment and 3 weeks post treatment.
Innate and adaptive immune cell populations were identified
and frequencies were assessed by flow cytometry (Figure 7A).
Population frequencies of CD4T cells, CD8T cells, neutrophils
(PMNs) and macrophages remain similar between LZD or
LZD+IL-1Rn, indicating that IL-1Rn did not significantly alter
the frequencies of immune populations in the airways. However,
we observed a possible reduction in neutrophils post treatment
in both groups. Therefore, we pooled LZD and LZD+IL-1Rn
treated animals and compared pre and post treatment immune
populations. Although macrophage populations were relatively
unchanged, there was a significant reduction in neutrophil
frequency in the BAL after 3 weeks of treatment with LZD,
regardless of IL-1Rn (p = 0.0098). To determine whether
the cytokine milieu in the airways changed during treatment,
a subset of 3 animals per group were chosen at random
for analysis by multi-plex using 10X concentrated BAL fluid
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FIGURE 5 | Addition of IL-1Rn does not modify efficacy of LZD-bacterial killing. Bacterial burden is shown after 4 weeks of LZD (blue) or LZD+IL-1Rn (red) treatment.
(A) Total thoracic (lung + lymph nodes) and lung CFU; each data point represents one macaque. Total thoracic CFU from three similarly infected untreated historical
control macaques (black) are included as reference for untreated CFU at this time point but excluded from statistical analysis. Lung (granulomas and lung tissue) are
shown separately. The percent of all lung granulomas that were CFU+ per monkey is shown. (B) CFU of all thoracic lymph nodes with data points representing CFU
from one macaque. CFU+ lymph nodes show the CFU from each thoracic lymph node in any animal that was Mtb+. For (A,B), p-values were determined by
Mann-Whitney test. (C) PET CT scans from pre-treatment were used to model predicted CFU prior to HDT initiation and compared to actual CFU determined at time
of necropsy. The predicted change in CFU was determined by: Actual total thoracic CFU post-treatment—Predicted total thoracic CFU interval (predicted from
pre-drug-treatment scan). Bars represent mean of prediction intervals and error whiskers represent the lower and upper bounds of the difference between final total
CFU and predicted CFU prior to drug treatment.
(Figure 7B). Statistical analysis was performed on combined
treatment groups to only compare pre- and post-treatment
changes. We assessed IL-1β and IL-1RA and saw no significant
changes after treatment (IL-1β p = 0.1562, IL-1RA p = 0.1250).
Interferon-inducible T cell alpha chemoattractant (I-TAC) is
upregulated in response in interferons and IL-1 and is generally
an indicator of inflammation, which appeared to be reduced post
treatment, however was not statistically significant (p = 0.0625).
IL-8, a neutrophil chemoattractant, was significantly reduced
after treatment, mirroring the reduction in neutrophil frequency
observed by flow cytometry and the mouse data. These data
suggest that treatment with either LZD or LZD+IL-1Rn rapidly
reduces inflammatory signatures associated with TB disease in
the airways.
IL-1 Blockade Modulates Granuloma
Environment and Pathology
To determine whether IL-1Rn modulated immune responses at
the site of infection, we chose at random 5 granulomas per animal
(25 per treatment group) and performed a multi-plex analysis of
granuloma supernatants (Figure 8A). There were no significant
differences in IL-1β, IL-1RA, or IL-18 levels in either treatment
group. IL-2 and IL-17 are correlated with protective immune
responses during TB (31) and while IL-2 levels in LZD+IL-
1Rn treatment were not statistically higher (p = 0.0882), a
statistically significant increase in IL-17a in LZD+IL-1Rn treated
animals was observed. While there are granulomas that have
no detectable IL-17, this results are still biologically significant
given that only 5 of 25 granulomas from LZD only treated
macaques had detectable IL-17, while 11 of 25 granulomas
from LZD+IL-1Rn treated macaques had detectable IL-17.
Interestingly, G-CSF/CSF-3 levels were also significantly higher
in LZD+IL-1Rn treated granulomas (p = 0.0004). These results
indicate IL-1Rn immune modulation occurs in the granuloma
environment. While we did not see a significant difference
in granuloma inflammation by FDG SUVR between treatment
groups (Figure 4C), we next questioned whether the changes
in cytokines observed in multiplex assays could be associated
with change in SUVR by PET CT. Therefore, we performed
linear regression analyses comparing cytokines detected by
multiplex and granuloma inflammation (FDG SUVR) and found
a positive correlation between IL-1β and fold change of SUVR in
LZD+IL-1Rn granulomas (Figure 8B). These data indicate that
change in inflammation (fold change of FDG SUVR) is correlated
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FIGURE 6 | Linezolid-associated bone marrow suppression was not observed in macaques. Bone marrow was acquired from the sternum of all macaques at
necropsy after 4 weeks LZD or LZD+IL-1Rn. A portion was used for flow cytometric analysis of erythroid progenitor populations and the rest for histopathology
analysis. (A) A schematic of erythropoiesis indicating the stage of differentiation and corresponding expression levels of phenotyping markers (CD235a and CD71) and
progenitor ratios (1:2:4:8). Included is the gating strategy to identify progenitor populations and an example of MitoTracker staining. (B) The ProE:EryC ratio (left) of
each animal, including untreated TB only macaques (black) from other ongoing unpublished studies. A single uninfected animal (open circle) is shown as reference,
the dotted line indicates the homeostatic ratio of 1:8. MitoTracker MFI (right) is shown for each macaque per treatment group. Kruskal-Wallis test was performed to
compare the three groups (excluding uninfected macaque) and p-values are shown in the graphs. (C) Representative H&E images from sternal bone marrow acquired
at necropsy, 20x (left) and 40x (right) are shown.
with levels of IL-1β in the granuloma. The IL-1 pathway
is associated with fibrosis, which increases in granulomas
during drug treatment (32). Furthermore, IL-17 and G-CSF
are also associated with fibrosis (33). To determine whether
immunomodulation by IL-1Rn changed granuloma pathology,
granulomas suitable for histological analysis were evaluated by
a study blinded pathologist and lesions were categorized based
on treatment groups and descriptive qualities (Figure 8C). Of
lesions acquired from LZD only animals, ∼71% were identified
as fibrotic (n = 40/56), while those treated with LZD+IL-
1Rn had ∼85% fibrotic lesions (n = 39/46) with no significant
difference in frequency of fibrotic lesions between treatment
groups.We also compared the frequency of granulomas that were
deemed necrotizing or non-necrotizing (“other” indicates neither
categorization). Granulomas from LZD+IL-1Rn treated animals
had significantly more non-necrotizing granulomas (∼74%,
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FIGURE 7 | LZD and LZD_IL-1Rn reduce inflammatory signatures in BAL. Bronchoalveolar lavages (BAL) were acquired pre-treatment and 3 weeks post-treatment
with LZD (blue) or LZD+IL-1Rn (red). (A) Cells were analyzed by flow cytometry to determine frequency changes in CD4T cells (CD3+CD4+), CD8T cells
(CD3+CD8+), macrophages (CD11b+CD206+), and neutrophils (CD11b+Calprotectin+). Wilcoxon signed rank test was performed to determine differences before
and after drug treatment, regardless of group (LZD and LZD+IL-1Rn combined). (B) BAL fluid was concentrated 10X and assessed by multiplex assay for changes in
inflammatory cytokines and chemokines for a random subset of samples (n = 3 per treatment group). Wilcoxon signed rank test was performed to determine
differences before and after drug treatment, regardless of group (LZD and LZD+IL-1Rn combined).
n= 34/46), compared to those from LZD alone treated macaques
(∼46%, n = 26/56). The proportion of necrotizing granulomas
was significantly lower in the LZD+IL-1Rn treatment group
(13.04%, n = 6/56) compared to LZD alone (30.36%, n = 17/56)
(p = 0.0151). These data suggest that addition of IL-1Rn
influences inflammation and antibiotic-associated pathology
dynamics of granulomas.
DISCUSSION
HDTs are a tantalizing solution to improve TB therapy,
however the complexities of host-pathogen interactions and
host variability call for rigorous pre-clinical testing before
implementation in humans. Here, we sought to determine the
efficacy and safety of an HDT for TB comprised of LZD and IL-
1Rn. IL-1 plays a complex role during TB, as IL-1 is important
for early control of infection (5, 7, 8, 34, 35), yet is also associated
with pathology at later times (10, 11). To validate the safety of IL-
1Rn in this context, we first assessed the effects of IL-1 inhibition
on TB disease progression in mice, using treatment regimens
designed to concentrate on established disease. In C57BL/6,
Nos2−/− and C3HeB/FeJ mice, αIL-1R1 blockade reduced PMN
infiltrates that are associated with pathological inflammation and
did not impair bacterial control. The effect on bacterial control
differs from a recent report in which lung bacterial burdens were
increased by a similar αIL-1R1 treatment in C57BL/6 or C57BL/6
animals carrying the super susceptibility to tuberculosis-1 (Sst1)
allele (25).We hypothesize that these differences are related to the
timing of treatment, relative to the onset of adaptive immunity.
Once infection is established, bacterial control is mediated
predominantly via T cell functions, potentially reducing the
importance of IL-1 dependent mechanisms (36). According to
this model, the effect of IL-1 inhibition will depend on the timing
of administration, as well as experimental factors that alter the
timing of T cell priming and expansion, such as bacterial strain
and dose. Regardless, our data indicate that IL-1 blockade can be
beneficial in the context of established disease.
Any HDT will be administered in conjunction with
antimicrobial therapy. When co-administered with LZD,
blockade of IL-1R1 reduced PMN infiltrates in the mouse
models, compared to the antibiotic alone. Despite differences
between animal models and the IL-1 antagonists used in each
model, we observed a similar anti-inflammatory effect in both
mouse and primate systems. In macaques, IL-1Rn in conjunction
with LZD significantly reduced overall lung inflammation as
assessed by PET CT while LZD alone was more variable. IL-1Rn
did not significantly enhance bacterial clearance compared to
LZD alone, which was not surprising as we did not expect IL-1Rn
to have direct antibacterial functions. However, it was important
to assess bacterial burden during IL-1Rn treatment to ensure
IL-1 blockade did not modulate host-mediated antibacterial
mechanisms in granulomas and lymph nodes. In CFU positive
lymph nodes, we observed a slight reduction in bacterial burden
with IL-1Rn that approached significance (p = 0.0965). Further
studies should include assessing the influence of drug treatment
and immunomodulation in lymph nodes, as thoracic lymph
nodes are recognized as a site of Mtb persistence (29).
To further assess the effects of IL-1Rn modulation of immune
responses, we observed a decrease in neutrophils (PMNs) and a
corresponding decrease in IL-8 in the airways of both treatment
group (LZD or LZD+IL-1Rn). This indicated LZD alone was
Frontiers in Immunology | www.frontiersin.org 14 May 2020 | Volume 11 | Article 891
Winchell et al. Evaluation of HDT for Tuberculosis
FIGURE 8 | Inflammation modulation by HDT influences granuloma resolution. (A) Randomly selected granulomas (n = 5 per macaque, n = 25 per treatment group)
were subjected to multiplex cytokine analysis to determine differences between treatment groups (colors indicate lesions from a single animal). p-values shown
determined by Mann-Whitney test. (B) A linear regression analysis of IL-1β levels and fold change in SUVR is depicted for LZD (blue) and LZD+IL-1Rn (red)
granulomas. R2 and p-values are provided in the legend. (C) Granulomas from LZD (n = 57) and LZD+IL-1Rn (n = 45) were examined by a pathologist (EK) and
categorized. We compared fibrotic (red) vs. non-fibrotic (gray) (left) frequencies between treatment groups. The right compares necrotizing (red) vs. non-necrotizing
(blue) and other (gray) granuloma frequencies. Fisher’s exact test p-values are reported.
efficacious in reducing PMN inflammatory signatures, likely due
to the reduction in bacterial burden. In granulomas, levels of
IL-1β, IL-1RA, and IL-18 were not affected by IL-1Rn treatment
in the subset examined. As IL-1Rn does not affect inflammasome
formation and function it is not surprising that IL-1β and
IL-18 production were minimally modulated by IL-1Rn. IL-
1RA levels remained unchanged between treatment groups,
which could be due to our method of detection or kinetics
of consumption. Our multiplex analysis is specific for non-
human primates and may not recognize recombinant human
IL-1RA like Anakinra. In LZD+IL-1Rn treated granulomas we
found a strong positive correlation between IL-1β levels and
fold-change in SUVR, a surrogate for inflammation. These data
highlight the relationship between IL-1β and inflammation in
granulomas, further supporting the potential of IL-1 blockade
as an HDT. In TB, IL-2 and IL-17A have protective functions
however are primarily expressed by T cells (31). While IL-
1β has been reported to enhance IL-17A production by T
cells in mice, these studies have primarily used model-antigen
systems and may not reflect a chronic infection like TB (37).
IL-1 exacerbates pathology later in TB infection, indicating the
effects of IL-1 on adaptive immunity are complex and likely
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dependent on the host system and infection model being used.
G-CSF was increased in granulomas from LZD+IL-1Rn treated
macaques which, combined with our observations of reduced
PMN infiltrates in mouse lungs and macaque airways, indicates
a paradoxical role of G-CSF as a neutrophil differentiation
factor (38). However, in a model of LPS-induced lung injury
G-CSF blockade induced accumulation of PMNs and increased
inflammation in the lungs, indicating pulmonary inflammation
may not follow dogmatic rules of canonical inflammatory
pathways (38).
Lung fibrosis is modulated by the IL-1 pathway and while
fibrosis is associated with healing tissue, lung fibrosis can cause
secondary complications after TB disease resolution (2). We
have shown in previous studies that TB drug therapy induces
fibrosis in granulomas (32, 39). These studies in combination
with the correlation between IL-1β and SUVR led us to assess
whether LZD+IL-1Rn was associated with changes in granuloma
pathology.While we did not observe a difference in fibrosis, there
was a significant decrease in frequency of necrotizing granulomas
with IL-1Rn in addition to LZD therapy. Thus, while there is no
synergistic effect between IL-1Rn and LZD in promoting fibrosis
associated with drug clearance, the reduction in neutrophils
observed inmice andmacaques could skew granuloma resolution
toward a non-necrotizing lesion (40). Further studies with IL-
1Rn alone could elucidate these dynamics, however we designed
this macaque study with intention to be translatable to humans.
We could not justify an IL-1Rn only treated group as TB-
patients would receive anti-microbial therapy with any HDT
or immunomodulatory intervention. However, our findings give
precedence for further exploration of the potential of IL-1Rn as
an HDT for TB and will require additional studies to determine
mechanism and safety.
Our second goal was to abrogate LZD-associated bone
marrow suppression with IL-1Rn therapy, thereby increasing the
efficacy and therapy potential of LZD in TB. While we designed
our HDT to match the current FDA guidelines for LZD and
IL-1Rn schedules, this resulted in a lack of observable bone
marrow suppression in macaques. In hindsight, extending LZD
treatment beyond 4 weeks to induce bone marrow suppression
would have allowed assessment of IL-1Rn abrogation of LZD-
toxicity, however we initially designed the NHP studies to
reflect FDA guidelines for the therapeutics used at the time of
study initiation. In mice however, LZD-induced bone marrow
suppression was reduced with the addition of IL-1R1 antagonist,
supporting our initial hypothesis of the therapeutic potential of
IL-1Rn in reducing LZD toxicity. The role of IL-1 signaling is
consistent with the ability of IL-1 to suppress erythropoiesis in
mice by reducing the number of progenitors (41). The remaining
deficit in erythropoiesis during IL-1 blockade could reflect either
incomplete inhibition by IL-1Rn or an independent role of
inflammasome activation. Optimizing this effect will require
further work to understand the relative roles of IL-1 signaling and
inflammasome activation.
Overall, our data support previous findings in macaques that
LZD has superb efficacy against TB, administered here as a single-
drug given for only 4 weeks, supporting LZD as an antimicrobial
for MDR/XDR-TB cases (42). IL-1Rn therapy in conjunction
with LZDwas successful in reducing TB-associated inflammation
with no negative effects on bacterial clearance. Reduction in
inflammation with IL-1 blockade could have beneficial effects
in quelling more pathological inflammation due to IL-1 during
active disease (11). While we observed changes in granuloma
resolution (necrotizing vs. non-necrotizing), these effects long-
term are unknown. Fibrosis is associated with healing and is
observed in NHPs after drug treatment (32), however excess
fibrosis in the lung may not result in the best outcome for
TB patients’ long term. Given the link between fibrosis and
IL-1, perhaps other inflammatory pathways could be targeted
to reduce inflammation and enhance disease resolution. We
know TNF is essential for controlling TB disease, and less
specific anti-inflammatory agents can also inhibit the protective
immune response, which has left many hesitant to modulate
host inflammation as a therapy (43). However, our data
support the idea that immunomodulation during TB is not
always detrimental and suggests that more specific agents may
be beneficial.
The differences in bone marrow suppression between mice
and macaques highlights the importance of assessing HDTs
in multiple models prior to human trials, as there are clear
biological differences between the two models. Anakinra (IL-
1Rn) is already FDA-approved for adult and pediatric treatment
of other inflammatory disorders and our data provide pre-clinical
evidence for IL-1Rn consideration as potential therapy in TB.
Further safety and mechanism assessments in translatable animal
models are required, but one could envision IL-1Rn therapy to
limit destructive inflammation for severe cases of TB. While our
study emphasizes the importance of rigorous testing of HDTs for
TB in multiple translational models prior to implementation in
human trials, we also show that immunomodulation of the IL-1
pathway did not exacerbate TB disease.
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